Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1612 1632 1644 1655 1656
This examiner grants 48% of resolved cases
Erica Nicole Jones-Foster is an examiner in Tech Center 1600 and Art Unit 1612. The profile shows 79 resolved cases and an allowance rate of 48.1 percent. The total number of resolved cases establishes the reliability of the prosecution data. This specific percentage of 48.1 helps practitioners estimate the likelihood of an application reaching an allowance.
The interview lift is 44.7 percent. This figure shows the difference in allowance probability when an interview is conducted. Practitioners can use the 44.7 percent lift to evaluate the utility of direct communication with the examiner during prosecution. This metric serves as a guide for deciding whether to request a formal discussion.
The median days to allowance is 1262. This period represents the middle value of the time taken to reach an allowance. With 79 resolved cases, the 1262-day duration characterizes the experience for applications assigned to this examiner. Practitioners should plan for this timeline when seeking a grant in Art Unit 1612.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17784693 | Methods and compositions for modulating the glycosylation profile of proteins | Non-Final OA | Merck Patent GmbH |
| 17185196 | GENETICALLY MODIFIED BACTERIAL CELLS AND METHODS USEFUL FOR PRODUCING TETRAMETHYL PYRAZINE | Final Rejection | The Regents of the University of California |
| 17437232 | MICROBIAL TEST KIT, MICROBIAL TEST METHOD AND MICROBIAL TEST DEVICE | Non-Final OA | HITACHI HIGH-TECH CORPORATION |
| 17795939 | COMPOSITIONS COMPRISING LINEAR POLYRIBONUCLEOTIDES FOR PROTEIN MODULATION AND USES THEREOF | Non-Final OA | Flagship Pioneering Innovations VI, LLC |
| 18570018 | NONANIC ACID ESTERS | Final Rejection | Evonik Operations GmbH |
| 18594431 | METHOD FOR IDENTIFYING CANDIDATE THERAPEUTICS FOR ALZHEIMER'S DISEASE | Non-Final OA | UNIVERSITY OF SOUTH FLORIDA |
| 17430969 | MYC, CYCLIN T1 AND/OR CDK9 FOR USE IN THE TREATMENT OF DEGENERATIVE HEART AND CNS DISORDERS | Final Rejection | CAMBRIDGE ENTERPRISE LIMITED |
| 18351069 | ENZYMATIC MODIFICATION OF PHOSPHOLIPIDS IN FOOD | Final Rejection | INTERNATIONAL N&H DENMARK APS |
| 17299273 | Powder Detergent Compositions | Non-Final OA | Novozymes A/S |
| 18260225 | Methods and Compositions for Making Amide Compounds | Final Rejection | Genomatica, Inc. |
| 18036580 | USE OF THERAPEUTIC ENZYME FUSION PROTEIN IN PREVENTION AND TREATMENT OF RENAL DISEASES CAUSED BY OR ACCOMPANIED BY FABRY DISEASE | Final Rejection | HANMI PHARM. CO., LTD. |
| 18036538 | USE OF THERAPEUTIC ENZYME FUSION PROTEIN IN PREVENTION AND TREATMENT OF NEUROPATHY CAUSED BY OR ACCOMPANIED BY FABRY DISEASE | Final Rejection | HANMI PHARM. CO., LTD. |
| 17974506 | COMPOSITIONS FOR INCREASING ETHANOL PRODUCTION AND RELATED METHODS | Final Rejection | KEMIN INDUSTRIES, INC. |
| 17446393 | METHODS OF REFINING A GRAIN OIL COMPOSITION, AND RELATED SYSTEMS, COMPOSITIONS AND USES | Non-Final OA | POET Research, Inc. |
| 17945293 | PROBIOTICS FOR USE IN REDUCING THE INCIDENCE AND DURATION OF ILLNESS | Final Rejection | DUPONT NUTRITION BIOSCIENCES APS |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy